Bioinformatics, sequence assembly, transcriptomics, gene regulation networks, high throughput informatics for big data. Birol Lab is located at British Columbia Cancer Agency, Genome Sciences Centre.
High throughput data analysis, data standards, flow cytomety, GvHD biomarker identification, cluster identification.
Genetics of human cancer susceptibility, particularly lymphoma, and genetics of healthy aging and longevity. Family and population-based genetics studies. We use techniques such as genotyping and exome and whole genome sequencing.
We study the pharmacogenomics of drug response – particularly serious adverse drug reactions and the therapeutic failure of drugs. I have a particular interest in pediatric medicine and the variability in drug response.
We use genome-scale screens and molecular cell biology approaches in model organisms and mammalian cells to study how proteins are localized to cellular membranes, and how defects in this process results in neurodegeneration and cancer.
Human pedigree and population genetics, and mouse modeling of neurodegenerative disease – designed to inform therapeutic development.
Neurological mutant mice are used as entrees into studying the genetics, cell biology and development of genes that are critical to nervous system development.
Mammalian development, Transcriptional regulation and epigenetics, Hepatocyte differentiation, Heart valve formation, Signal transduction, Transgenic/knockout mice, Whole genome profiling
Bioinformatics, gene expression, gene regulation, genome sequence analysis and genome assembly.
Our research bridges the molecular mechanisms of epigenetic regulation with the social and environmental determinants of human health to develop a comprehensive understanding of biological embedding of early life experiences
Our research focus is on the role of genome instability in aging and cancer. For these studies we have developed powerful single cell DNA template strand sequencing technique (Strand-seq). See: https://www.bccrc.ca/dept/tfl/people/peter-m-lansdorp
Discovery of monogenic causes of human developmental or metabolic disorders; natural history of monogenic disorders; optimal management of mitochondrial disorders.
Interplay between transcription, DNA methylation and histone modifications in the germ line, early development and disease
Gene regulatory changes in malignancy, ribosomal variation in cancer, impact of transposable elements on mammalian genes.
Proteomics, protein-protein interactions, protein isoform function, alternative splicing.
Computational biology, regulatory networks, genetics of complex traits, psychiatric genetics, machine learning in computational biology, genomics.
Immune response to cancer; immunogenomics; adoptive T cell therapy; T cell engineering; oncolytic viruses; phase I clinical trials
Chromosomal etiology of intellectual disability/autism and cancer, Molecular cytogenetics, Identification of subtle chromosomal abnormalities using whole genome arrays.
Genetics and epigenetics related to fetal development and obstetrical complications of pregnancy such as fetal growth restriction, preterm birth, and birth defects. We use genomic and bioinformatic techniques/ tools to understand pathological processes related to placenta that affect the fetus and newborn.
1) Scope and impact of germline findings identified in next generation sequencing and the use of these technologies in oncology; 2) molecular diagnosis and characterization of hereditary cancer syndromes
Gene-based therapies for diseases of the brain and eye, cell-type specific MiniPomoters for rAAV delivery of gene augmentation and genome editing (CRISPR/cas9) therapies to cure mouse models of the human disease.
We study how transcriptional regulation affects metabolism and stress responses in C. elegans (worm), mice, and mammalian cells. Our goal is to identify genes and mechanisms that can be targeted in diseases such as cancers, diabetes, and neurodegenerative disorders, all of which have links to dysreguated stress response and metabolism. Our work is highly collaborative and uses state of the art genetic, genomic, molecular and computational biology approaches.
We implement second generation sequencing technologies for the identification of mutations causing highly prevalent neurological diseases, with primary focus on multiple sclerosis, and characterize new models of human disease based on these discoveries for the development of novel and more effective treatments.
Computational analysis of human genome sequence for the study of gene regulation and rare pediatric disorders.
We are a stem cell bioengineering lab that develops robust technologies to control propagation and fate of stem cells and their derivatives, primarily focusing on blood differentiation from pluripotent stem cells.